Zimmer Holdings announced Thursday that it will acquire Biomet in a nearly $13.35 billion transaction that will provide it with a leading position in the $45 billion musculoskeletal industry.
The merger between the two Warsaw, IN–based orthopedic device makers is expected to close early next year pending customary closing conditions and regulatory approvals.
The $13.35 billion includes cash, stock, and the assumption of debt.
|Refresh your medical device industry knowledge at MD&M East, June 9–12, 2014 in New York City.|
Zimmer officials see enhanced innovation and cross-selling opportunities from the acquisition. Cash flows from operations are expected to increase by 1.5 times Zimmer's stand-alone estimates.
“We believe that current demographic and macroeconomic trends affecting the healthcare industry will reward companies that successfully partner with other key stakeholders to improve patient care in a cost-effective manner. … This combination is about achieving growth and cultivating best-in-class solutions,” David Dvorak, Zimmer president and CEO, said in a news release.
Dvorak also said: “We are equally committed to delivering quality products and outstanding clinical results and to legal and ethical behavior in the markets where we do business. And as companies focused almost exclusively in the musculoskeletal industry, we are passionate about orthopaedics and the related medical technology markets that we serve."
- Laser Ablation - Supplier Resource
- Learning from Hospital Acquired Infections (HAIs): Understanding Current Reprocessing Regulations, Product Validation and Clinical Human Factors - Webcast
- Best Practices for Medical Device Manufacturers to Ensure Quality - Supplier Resource
- Custom Products List - Supplier Resource
- Manufacturing - Supplier Resource
- Risky Business: Why Excluding Suppliers from Your Quality Processes Could Cost You - Supplier Resource